firstwordpharmaJanuary 16, 2019
Tag: Bill Yuan , Chairman , pharmaceutical , Bill Yuan
CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has appointed William (Bill) Yuan to Chairman of the Board and Dr. Gene Salkind to its Board of Directors. These appointments will expand the size of the board to five with more members expected to be added in Q1.
Bill Yuan has served on CURE’s Board of Directors for 2 years and Dr. Gene Salkind has been an advisor and investor in CURE.
"Having previously worked with Bill to build and successfully exit two thriving companies, I can attest to his vast corporate governance experience and executive managerial prowess, and I am honored to gain Bill’s support as Chairman of CURE’s board of directors," said Robert Davidson, CEO of CURE Pharmaceutical. "Bill’s qualifications, vision, outstanding skill set, and guidance will contribute to CURE’s profitability and create shareholder value. We are also thrilled that Dr. Salkind will now be contributing his vast clinical and life sciences knowledge into advancing CURE’s product pipeline as a board member."
With more than 20 years of global finance experience, Bill Yuan has held positions with Wall Street’s tier one firms including Goldman Sachs (M&A), Morgan Stanley SB (Capital Markets), and Merrill Lynch (Corporate Institutional Asset Management). Bill has advised Fortune 100 companies across multiple continents, with a specialization in Asia, and China in particular. His leadership, track record and exclusive network of corporate and institutional clients and investors will contribute key building blocks for CURE to achieve the highest level of success.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: